Freenome (NASDAQ:FRNM) Upgraded to Strong-Buy at TD Cowen

Freenome (NASDAQ:FRNM) was upgraded by analysts at TD Cowen to a “strong-buy” rating in a note issued to investors on Tuesday,Zacks.com reports.

FRNM has been the topic of a number of other reports. Jefferies Financial Group began coverage on shares of Freenome in a report on Monday. They set a “buy” rating and a $17.00 price objective on the stock. Leerink Partners began coverage on shares of Freenome in a report on Friday, August 14th. They set an “outperform” rating and a $18.00 target price for the company. Finally, BTIG Research started coverage on shares of Freenome in a report on Monday. They set a “buy” rating and a $17.00 price target on the stock. One analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $17.25.

Freenome Trading Up 1.3%

FRNM stock opened at $13.63 on Tuesday. Freenome has a one year low of $9.97 and a one year high of $14.26.

Freenome Company Profile

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.